Ms. Leah Liu joined Laekna Therapeutics in 2021 as Chief Financial Officer. She is responsible for the company’s capital market-related activitiess, including financing, IPO and investor relations.  

Prior to joining Laekna, Ms. Liu was the Investor Relations Senior Director for I-Mab Biopharma, where she led spearheaded its US$418 million private investment in public equity (PIPE) led by investment from Hillhouse Capital. This was the largest PIPE ever for a Chinese biotech company. She was also responsible for all capital markets and investor relations strategies and activities of the Nasdaq listed company.  

Ms. Liu has rich experience in the finance and investment sector industries. Previously, she worked for Cloudminds Technology and Xtep respectively as head of investor relations and capital markets, and received many major investor relations awards.  Prior to that, she held positions at major international investment banks including HSBC, Daiwa Securities, and Lazard.    

Ms. Liu graduated with Dean’s List honors from Johns Hopkins University, obtaining her M.S. degree in Cellular Molecular Biology, and two bachelor’s degrees in biology and international studies in four years with full Bloomberg Scholarship.